வாலி குர்ரன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வாலி குர்ரன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வாலி குர்ரன் Today - Breaking & Trending Today

Lantheus Selects GenesisCare to Administer First Commercial Dose of PYLARIFY®, the First and Only FDA-Approved PSMA PET Imaging Agent for Men with Prostate Cancer

/PRNewswire/ GenesisCare one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom today announced it will. ....

United States , New South Wales , United Kingdom , Kishorek Dass , Dan Collins , Angharad Bhardwaj , Boca Raton , Wally Curran , Us Communications , American Cancer Society , Radiation Oncologist , Genesiscare Global Chief Medical , Medical Officer , Century Oncology , Australian Headquartered , ஒன்றுபட்டது மாநிலங்களில் , புதியது தெற்கு வேல்ஸ் , ஒன்றுபட்டது கிஂக்டம் , டான் கோலின்ஸ் , போகா ரேடோந் , வாலி குர்ரன் , எங்களுக்கு தகவல்தொடர்புகள் , அமெரிக்கன் புற்றுநோய் சமூகம் , கதிர்வீச்சு புற்றுநோயியல் நிபுணர் , மருத்துவ அதிகாரி , சிஇஎன்டியுவ்ஆர்ஒய் புற்றுநோயியல் ,

GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer

GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer
on February 23 2021 9:00 PM
SYDNEY & LAGUNA HILLS, Calif. (BUSINESS WIRE) #breastcancerawareness GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx
TM), a leader in molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes.
DCISionRT
® is a precision medicine test for women diagnosed with DCIS (Ductal Carcinoma in situ) or Stage 0 breast cancer who are treated with breast-conserving surgery. The DCISionRT test, developed by PreludeDx, assesses a woman’s 10-year risk of recurrence of DCIS or development of invasive breast cancer. The test provides predictive information regarding recurrence risk, allowing physicians to better select those patien ....

United States , New South Wales , United Kingdom , Dan Collins , Vvan Seijen , Angharad Bhardwaj , Bronte Kerr , Daniel Forche , Wally Curran , Contract Research Organization , National Center , National Surgical Adjuvant Breast , National Cancer Institute , Prelude Corporation Preludedx , Prelude Corporation , University Of California San Francisco , Breast Cancer Network Australia , National Surgical Adjuvant Breast Project , Ductal Carcinoma , Biotechnology Information , Global Chief Executive Officer , Chief Executive Officer , Global Chief Medical Officer , Cancer Network Australia , Bowel Project Collaborating , Century Oncology ,